TNFRSF11A and breast cancer: The strength of our work resides in the fact that two independent studies, a clinical trial and preclinical research on tumor-prone mouse models, equally conclude that the inhibition of RANK signaling increases the anti-tumor immune response and set the basis for additional trials combining denosumab with immunotherapy in presumably immune “cold” luminal BC.